CD28 and congenital rubella syndrome: Even though CD28 signal indeed enhanced fusion protein antibodies in pre-clinical research, we cannot ignore the lessons from the CD28 super agonist TGN1412 trial, in which six volunteers suffered life-threatening cytokine-release syndrome (CRS) [19, 20].